Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease

Brain

Volumn 132, Issue 7, 2009, Pages 1820-1832

  Liu, Fei ^a,b   Shi, Jianhua ^b   Tanimukai, Hitoshi ^a   Gu, Jinhua ^b   Gu, Jianlan ^b   Grundke Iqbal, Inge ^a   Iqbal, Khalid ^a   Gong, Cheng Xin ^a  

^a NEW YORK STATE INSTITUTE FOR BASIC RESEARCH IN DEVELOPMENTAL DISABILITIES   (United States)

^b NANTONG UNIVERSITY   (China)

Author keywords

glucose metabolism; neurofibrillary degeneration; O GlcNAcylation; protein phosphatase 2A; tau phosphorylation

Indexed keywords

CYTOPLASM PROTEIN; HEXOSAMINE; N ACETYLGLUCOSAMINE; PHOSPHOPROTEIN PHOSPHATASE 2A; SHORT HAIRPIN RNA; TAU PROTEIN;

AGED; ALZHEIMER DISEASE; ANIMAL TISSUE; ARTICLE; CELL STRAIN HEK293; CONTROLLED STUDY; DIET RESTRICTION; DOWN REGULATION; ENZYME ACTIVITY; ENZYME INHIBITION; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; HUMAN TISSUE; MOUSE; NERVE CELL DEGENERATION; NEUROFILAMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; RAT;

AGED, 80 AND OVER; ALZHEIMER DISEASE; BRAIN; CELLS, CULTURED; DOWN-REGULATION; FEMALE; GLUCOSE; HEXOSAMINES; HUMANS; MALE; N-ACETYLGLUCOSAMINYLTRANSFERASES; PHOSPHORYLATION; PROTEIN PHOSPHATASE 2; TAU PROTEINS;

EID: 67650072530     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awp099     Document Type: Article

References (66)

1. Alonso AD, Mederlyova A, Novak M, Grundke-Iqbal I, Iqbal K. Promotion of hyperphosphorylation by frontotemporal dementia tau mutations. J Biol Chem 2004; 279: 34873-81.
2. Alonso AD, Zaidi T, Grundke-Iqbal I, Iqbal K. Role of abnormally phosphorylated tau in the breakdown of microtubules in Alzheimer's disease. Proc Natl Acad Sci USA 1994; 91: 5562-6.
3. Alonso AD, Zaidi T, Novak M, Barra HS, Grundke-Iqbal I, Iqbal K. Interaction of tau isoforms with Alzheimer's disease abnormally hyper-phosphorylated tau and in vitro phosphorylation into the disease-like protein. J Biol Chem 2001a; 276: 37967-73.
4. Alonso AD, Zaidi T, Novak M, Grundke-Iqbal I, Iqbal K. Hyperphosphorylation induces self-assembly of tau into tangles of paired helical filaments/straight filaments. Proc Natl Acad Sci USA 2001b; 98: 6923-8.
5. Arnold CS, Johnson GV, Cole RN, Dong DL, Lee M, Hart GW. The microtubule-associated protein tau is extensively modified with O-linked N-acetylglucosamine. J Biol Chem 1996; 271: 28741-4.
6. Blurton-Jones M, Laferla FM. Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 2006; 3: 437-48.
7. Braak H, Braak E. Staging of Alzheimer's disease-related neurofibrillary changes. Neurobiol Aging 1995; 16: 271-8; discussion 278-84.
8. de Leon MJ, Convit A, Wolf OT, Tarshish CY, DeSanti S, Rusinek H, et al. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-D-glucose/poitron-emission tomography (FDG/PET). Proc Natl Acad Sci USA 2001; 98: 10966-71.
9. Deng Y, Li B, Liu F, Iqbal K, Grundke-Iqbal I, Brandt R, et al. Regulation between O-GlcNAcylation and phosphorylation of neurofilament-M and their dysregulation in Alzheimer's disease. FASEB J 2008; 22:138-45.
10. Drzezga A, Grimmer T, Riemenschneider M, Lautenschlager N, Siebner H, Alexopoulus P, et al. Prediction of individual clinical outcome in MCI by means of genetic assessment and (18)F-FDG PET. J Nucl Med 2005; 46: 1625-32.
11. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, et al. Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003; 30: 1104-13.
12. Fath T, Eidenmuller J, Brandt R. Tau-mediated cytotoxicity in a pseudo- hyperphosphorylation model of Alzheimer's disease. J Neurosci 2002; 22: 9733-41.
13. Fehm HL, Kern W, Peters A. The selfish brain: competition for energy resources. Prog Brain Res 2006; 153: 129-40.
14. Goedert M, Jakes R, Qi Z, Wang JH, Cohen P. Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP- dependent protein kinase. J Neurochem 1995; 65: 2804-7.
15. Gong CX, Iqbal K. Hyperphosphorylation of microtubule-associated protein tau: a promising therapeutic target for Alzheimer's disease. Curr Med Chem 2008; 15: 2321-8.
16. Gong CX, Lidsky T, Wegiel J, Zuck L, Grundke-Iqbal I, Iqbal K. Phosphorylation of microtubule-associated protein tau is regulated by protein phosphatase 2A in mammalian brain. Implications for neurofibrillary degeneration in Alzheimer's disease. J Biol Chem 2000; 275: 5535-44.
17. Gong CX, Liu F, Grundke-Iqbal I, Iqbal K. Post-translational modifications of tau protein in Alzheimer's disease. J Neural Transm 2005; 112: 813-38.
18. Gong CX, Shaikh S, Wang JZ, Zaidi T, Grundke-Iqbal I, Iqbal K. Phosphatase activity toward abnormally phosphorylated tau: decrease in Alzheimer's disease brain. J Neurochem 1995; 65: 732-8.
19. Gong CX, Singh TJ, Grundke-Iqbal I, Iqbal K. Phosphoprotein phosphatase activities in Alzheimer's disease brain. J Neurochem 1993; 61: 921-7.
20. Grundke-Iqbal I, Iqbal K, Tung YC, Quinlan M, Wisniewski HM, Binder LI. Abnormal phosphorylation of the microtubule-associated protein tau (tau) in Alzheimer cytoskeletal pathology. Proc Natl Acad Sci USA 1986; 83: 4913-7.
21. Hanger DP, Byers HL, Wray S, Leung KY, Saxton MJ, Seereeram A, et al. Novel phosphorylation sites in tau from Alzheimer brain support a role for casein kinase 1 in disease pathogenesis. J Biol Chem 2007; 282: 23645-54.
22. Heiss WD, Szelies B, Kessler J, Herholz K. Abnormalities of energy metabolism in Alzheimer's disease studied with PET. Ann N Y Acad Sci 1991; 640: 65-71.
23. Iqbal K, Grundke-Iqbal I. Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathol 2005; 109: 25-31.
24. Iqbal K, Grundke-Iqbal I, Zaidi T, Merz PA, Wen GY, Shaikh SS, et al. Defective brain microtubule assembly in Alzheimer's disease. Lancet 1986; 2: 421-6.
25. Ivancevic V, Alavi A, Souder E, Mozley PD, Gur RE, Benard F, et al. Regional cerebral glucose metabolism in healthy volunteers determined by fluordeoxyglucose positron emission tomography: appearance and variance in the transaxial, coronal, and sagittal planes. Clin Nucl Med 2000; 25: 596-602.
26. Jackson GR, Wiedau-Pazos M, Sang TK, Wagle N, Brown CA, Massachi S, et al. Human wild-type tau interacts with wingless pathway components and produces neurofibrillary pathology in Drosophila. Neuron 2002; 34: 509-19.
27. Khatoon S, Grundke-Iqbal I, Iqbal K. Brain levels of microtubule- associated protein tau are elevated in Alzheimer's disease: a radioim- muno-slot-blot assay for nanograms of the protein. J Neurochem 1992; 59: 750-3.
28. Kopke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I. Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer's disease. J Biol Chem 1993; 268: 24374-84.
29. Kreppel LK, Hart GW. Regulation of a cytosolic and nuclear O-GlcNAc transferase. Role of the tetratricopeptide repeats. J Biol Chem 1999; 274: 32015-22.
30. Kuhl DE, Metter EJ, Riege WH, Phelps ME. Effects of human aging on patterns of local cerebral glucose utilization determined by the [18F]fluorodeoxyglucose method. J Cereb Blood Flow Metab 1982; 2: 163-71.
31. Lee HG, Perry G, Moreira PI, Garrett MR, Liu Q, Zhu X, et al. Tau phosphorylation in Alzheimer's disease: pathogen or protector? Trends Mol Med 2005; 11: 164-9.
32. Li X, Lu F, Wang JZ, Gong CX. Concurrent alterations of O-GlcNAcylation and phosphorylation of tau in mouse brains during fasting. Eur J Neurosci 2006; 23: 2078-86.
33. Liu F, Grundke-Iqbal I, Iqbal K, Gong CX. Contributions of protein phosphatases PP1, PP2A, PP2B and PP5 to the regulation of tau phosphorylation. Eur J Neurosci 2005; 22: 1942-50.
34. Liu F, Iqbal K, Grundke-Iqbal I, Hart GW, Gong CX. O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci USA 2004; 101: 10804-9.
35. Liu Y, Liu F, Iqbal K, Grundke-Iqbal I, Gong CX. Decreased glucose transporters correlate to abnormal hyperphosphorylation of tau in Alzheimer's disease. FEBS Lett 2008b; 582: 359-64.
36. Liu F, Zaidi T, Iqbal K, Grundke-Iqbal I, Gong CX. Aberrant glycosylation modulates phosphorylation of tau by protein kinase A and depho- sphorylation of tau by protein phosphatase 2A and 5. Neuroscience 2002; 115: 829-37.
37. Liu R, Zhou XW, Tanila H, Bjorkdahl C, Wang JZ, Guan ZZ, et al. Phosphorylated PP2A (tyrosine 307) is associated with Alzheimer neurofibrillary pathology. J Cell Mol Med 2008a; 12: 241-57.
38. Loessner A, Alavi A, Lewandrowski KU, Mozley D, Souder E, Gur RE. Regional cerebral function determined by FDG-PET in healthy volunteers: normal patterns and changes with age. J Nucl Med 1995; 36: 1141-9.
39. Loring JF, Wen X, Lee JM, Seilhamer J, Somogyi R. A gene expression profile of Alzheimer's disease. DNA Cell Biol 2001; 20:683-95.
40. Love DC, Hanover JA. The hexosamine signaling pathway: deciphering the ''O-GlcNAc code''. Sci STKE 2005; 2005: re13.
41. Lucas JJ, Hernandez F, Gomez-Ramos P, Moran MA, Hen R, Avila J. Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J 2001; 20: 27-39.
42. McGeer EG, McGeer PL, Akiyama H, Harrop R. Cortical glutaminase, beta-glucuronidase and glucose utilization in Alzheimer's disease. Can J Neurol Sci 1989; 16: 511-5.
43. McGeer EG, Peppard RP, McGeer PL, Tuokko H, Crockett D, Parks R, et al. 18Fluorodeoxyglucose positron emission tomography studies in presumed Alzheimer cases, including 13 serial scans. Can J Neurol Sci 1990; 17: 1-11.
44. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, et al. Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE 2007; 2: e536.
45. Mielke R, Herholz K, Grond M, Kessler J, Heiss WD. Clinical deterioration in probable Alzheimer's disease correlates with progressive metabolic impairment of association areas. Dementia 1994; 5: 36-41.
46. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE. A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995; 36:1238-48.
47. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991; 41: 479-86.
48. Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Mandel F, Alexander GE, et al. The metabolic topography of normal aging. J Cereb Blood Flow Metab 1996; 16: 385-98.
49. Mosconi L, Perani D, Sorbi S, Herholz K, Nacmias B, Holthoff V, et al. MCI conversion to dementia and the APOE genotype: a prediction study with FDG-PET. Neurology 2004; 63: 2332-40.
50. Mosconi L, Tsui WH, Rusinek H, De Santi S, Li Y, Wang GJ, et al. Quantitation, regional vulnerability, and kinetic modeling of brain glucose metabolism in mild Alzheimer's disease. Eur J Nucl Med Mol Imaging 2007; 34: 1467-79.
51. Pei JJ, Sjogren M, Winblad B. Neurofibrillary degeneration in Alzheimer's disease: from molecular mechanisms to identification of drug targets. Curr Opin Psychiatry 2008; 21: 555-61.
52. Perez M, Hernandez F, Gomez-Ramos A, Smith M, Perry G, Avila J. Formation of aberrant phosphotau fibrillar polymers in neural cultured cells. Eur J Biochem 2002; 269: 1484-9.
53. Perry G, Nunomura A, Hirai K, Takeda A, Aliev G, Smith MA. Oxidative damage in Alzheimer's disease: the metabolic dimension. Int J Dev Neurosci 2000; 18: 417-21.
54. Perry G, Nunomura A, Raina AK, Aliev G, Siedlak SL, Harris PL, et al. A metabolic basis for Alzheimer's disease. Neurochem Res 2003; 28:1549-52.
55. Pietrini P, Azari NP, Grady CL, Salerno JA, Gonzales-Aviles A, Heston LL, et al. Pattern of cerebral metabolic interactions in a subject with isolated amnesia at risk for Alzheimer's disease: a longitudinal evaluation. Dementia 1993; 4: 94-101.
56. Planel E, Miyasaka T, Launey T, Chui DH, Tanemura K, Sato S, et al. Alterations in glucose metabolism induce hypothermia leading to tau hyperphosphorylation through differential inhibition of kinase and phosphatase activities: implications for Alzheimer's disease. J Neurosci 2004; 24: 2401-11.
57. Planel E, Yasutake K, Fujita SC, Ishiguro K. Inhibition of protein phosphatase 2A overrides tau protein kinase I/glycogen synthase kinase 3 beta and cyclin-dependent kinase 5 inhibition and results in tau hyperphosphorylation in the hippocampus of starved mouse. J Biol Chem 2001; 276: 34298-306.
58. Salmon E, Maquet P, Sadzot B, Degueldre C, Lemaire C, Franck G. Decrease of frontal metabolism demonstrated by positron emission tomography in a population of healthy elderly volunteers. Acta Neurol Belg 1991; 91: 288-95.
59. Simpson IA, Chundu KR, Davies-Hill T, Honer WG, Davies P. Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease. Ann Neurol 1994; 35: 546-51.
60. Smith GS, de Leon MJ, George AE, Kluger A, Volkow ND, McRae T, et al. Topography of cross-sectional and longitudinal glucose metabolic deficits in Alzheimer's disease. Pathophysiologic implications. Arch Neurol 1992; 49: 1142-50.
61. Sontag E, Luangpirom A, Hladik C, Mudrak I, Ogris E, Speciale S, et al. Altered expression levels of the protein phosphatase 2A ABalphaC enzyme are associated with Alzheimer's disease pathology. J Neuropathol Exp Neurol 2004; 63: 287-301.
62. Sontag E, Nunbhakdi-Craig V, Lee G, Bloom GS, Mumby MC. Regulation of the phosphorylation state and microtubule- binding activity of Tau by protein phosphatase 2A. Neuron 1996;17: 1201-7.
63. Stozicka Z, Zilka N, Novak M. Risk and protective factors for sporadic Alzheimer's disease. Acta Virol 2007; 51: 205-22.
64. Su B, Wang X, Drew KL, Perry G, Smith MA, Zhu X. Physiological regulation of tau phosphorylation during hibernation. J Neurochem 2008; 105: 2098-108.
65. Vogelsberg-Ragaglia V, Schuck T, Trojanowski JQ, Lee VM. PP2A mRNA expression is quantitatively decreased in Alzheimer's disease hippocampus. Exp Neurol 2001; 168: 402-12.
66. Zhou XW, Gustafsson JA, Tanila H, Bjorkdahl C, Liu R, Winblad B, et al. Tau hyperphosphorylation correlates with reduced methylation of protein phosphatase 2A. Neurobiol Dis 2008; 31: 386-94.